Diagnostics Solutions Strategic Priorities
Transforming diagnostics in heart failure
Type-2 diabetes: Identifying heart failure early to improve outcome
Stages of heart failure¹
New NT-proBNP intended use (IU) to be launched in 2021
NYHA class
Progression of remodeling
Ils
E
=
Worsening symptoms
ACS
IV
Stage A
Stage B
Exacerbation
(attack)
Stage C
Structural heart disease
Signs & symptoms
Stage D
Refractory heart failure
Stage of HF
Hospitalization or death
due to cardiac disease
1.0
0.8
PONTIAC-I study"
proBNP >125 pg/mL
+ treatment (N = 150)
Controls (N = 150)
p = 0.035
0.6
5
10
15
20
24
Months
A 65%
Tomorrow's focus:
463 million
Today's focus:
type-2 diabetes patients²
64 million
patients³
Identify type-2 diabetes patients with high
cardiovascular risk to start effective drug treatment
1 Kato M. The Concept of Heart Failure. 2018 (doi.org/10.1007/978-4-431-56065-4_1); 2 Saeedi P et al., Diabetes Res Clin Pract 2019; 157: 107843; 3 Groenewegen A et al, Eur J Heart Failure 2020; 22: 1342;
4 Huelsmann M. et al. JACC. 2013, 62:1365, confirmatory clinical trials (RCTs) running both in Europe (NCT02817360, PONTIAC-II) and Asia (NCT04286399, ADOPT).
Roche
58View entire presentation